ArticleFrontiers in immunology2025
Impact of Sjögren's disease and its immunological characteristics on reaching remission or low disease activity state in systemic lupus erythematosus patients: a propensity score-matched longitudinal study.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Genetic variants associated with Sjögren's disease subtypes stratified by clinical feature.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Systemic lupus erythematosus (SLE) overlapping with Sjögren's disease (SjD) or not may progress differently in the clinical course. We aimed to explore the impact of SjD on lupus low disease activity state (LLDAS) or remission achievement in a real-world cohort. Methods: The medical records of patients in the Peking University First Hospital SLE (PKUFHS) cohort from 2007 to 2019 were retrospectively reviewed. Demographics, SLE and SjD features, treatment, and whether in LLDAS/remission on treatment (RONT) or not at each visit were collected. According to overlapped SjD and its immunological features, all patients were categorized into the following subgroups: SjD with anti-SSA single positivity, SjD with anti-SSA/SSB double positivity, SjD with baseline hypergammaglobulinemia, and those without SjD. The Cox proportional hazards model in propensity score-matched cohorts was used to estimate the impact of different SjD characteristics on LLDAS/RONT and each component after correcting for known confounders. Results: A total of 9,415 visits originating from 626 SLE patients were included. Overlapping SjD was identified in 77 (12.3%) patients. Patients with SLE overlapping SjD were significantly older at onset and predominantly female with more frequent hematological involvement. Overlapping SjD and anti-SSA/SSB double-positive SjD were associated with 29%-38% and 50%-53% reduction, respectively, in RONT achievement in SLE patients. Both overlapping SjD and SjD with baseline hypergammaglobulinemia acted as protectors for LLDAS achievement with 24% and 31% increments, respectively, and anti-SSA single-positive SjD showed no definite effect. The most affected target component was normal serology, with hazard ratios of 0.64-0.85 for overlapping SjD and anti-SSA/SSB double-positive SjD, and 1.15-1.24 for SjD with baseline hypergammaglobulinemia. Conclusions: Overlapping SjD facilitated reaching LLDAS yet hampered further RONT, anti-SSA/SSB double-positive SjD acted as a hazardous factor, SjD with baseline hypergammaglobulinemia acted as a protective factor, and anti-SSA single-positive SjD acted as an irrelevant factor for RONT achievement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.